Julian Baker’s Amicus Therapeutics FOLD Stock Holding History

Julian Baker’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-481,697	Closed	-$4.01M	–	132
2014 Q4	$4.01M	Hold	481,697	–	–	0.04%	77
2014 Q3	$2.87M	Hold	481,697	–	–	0.04%	80
2014 Q2	$1.61M	Hold	481,697	–	–	0.02%	93
2014 Q1	$997K	Sell	481,697 -33,375	-6%	-$83.4K	0.01%	98
2013 Q4	$1.21M	Hold	515,072	–	–	0.02%	86
2013 Q3	$1.2M	Hold	515,072	–	–	0.02%	76
2013 Q2	$1.2M	Buy	+515,072	New	+$1.58M	0.02%	66

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Julian Baker's FOLD Position: Q1 2015 in Review

Julian Baker sold out of Amicus Therapeutics (FOLD) in Q1 2015, closing a stake of 481,697 shares — an estimated $4.01M sold.

Julian Baker first reported a position in FOLD in Q2 2013 and held it in 7 quarters. The position peaked at $4.01M in Q4 2014. 125 funds tracked by Wall St. Rank hold FOLD as of Q1 2015.

Julian Baker reported no remaining Amicus Therapeutics position as of Q1 2015 after selling out during the quarter.
Julian Baker sold 481,697 Amicus Therapeutics shares in Q1 2015, an estimated $4.01M.
Julian Baker first reported a position in Amicus Therapeutics in Q2 2013 and held it in 7 quarters.
Julian Baker's Amicus Therapeutics position peaked at $4.01M in Q4 2014.
125 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2015.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.